SILO (Silo Pharma Inc.) stock: $1.84, $3.2M market cap, $5.2M cash, -$2.0M EV, $3.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
SPC-15
Preclinical · Active Modality: intranasal (soft mist nasal spray)
Target serotonin 4 (5-HT4) receptor
Partnerships Columbia University: exclusive global rights to develop and commercialize (exclusive license agreement entered Jul 1, 2024); Medspray Pharma BV: exclusive, non-revocable, worldwide license for proprietary soft mist nasal spray delivery technology (license agreement Nov 15, 2023, effective Oct 31, 2023)
Indications- Post-traumatic stress disorder (PTSD) (Preclinical)
- Stress-induced anxiety disorder (Preclinical)
Status note Lead product candidate. Pre-IND briefing package and meeting request submitted Jun 4, 2024; pre-IND meeting with FDA held Sep 2024 to align on the 505(b)(2) regulatory pathway. Studies required to support an IND submission completed; advancing toward human clinical trials.
SPU-16
Stage not disclosed · Terminated Modality: central nervous system-homing peptides
Partnerships University of Maryland, Baltimore: Master License Agreement (Feb 12, 2021) terminated Jul 8, 2025; subsequent exclusive option to negotiate a new commercial license expired unexercised on Mar 31, 2026
Indications- Multiple sclerosis (Stage not disclosed)
- Other neuroinflammatory pathology (Stage not disclosed)
Status note UMB license terminated Jul 8, 2025 and the option to negotiate a new license expired unexercised Mar 31, 2026; Silo no longer holds rights to this asset.
SP-26
Stage not disclosed · Active
Indications- Chronic pain, including fibromyalgia (Stage not disclosed)
Status note Provisional patent application filed Mar 2023; intended for development under the FDA 505(b)(2) regulatory pathway for repurposed drugs.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.